Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 12/20 | 0.55 |
| ▸ | CES1 | P23141 | 10/20 | 0.55 |
| ▸ | CES2 | O00748 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.46 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL969163 | 1.00 | FAAH (0.55) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL20590786 | 1.00 | FAAH (0.55) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL723653 | 0.91 | FAAH (0.65) | FAAHCES1MEN1CYP1A2KMT2A | |
| SCHEMBL31299556 | 0.90 | FAAH (0.50) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL16116786 | 0.86 | KMT2A (0.52) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL116286 | 0.85 | FAAH (0.57) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL3047322 | 0.83 | FAAH (0.55) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL2462129 | 0.83 | FAAH (0.55) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL29109867 | 0.83 | FAAH (0.55) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL2460155 | 0.83 | FAAH (0.55) | FAAHCES1CES2MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605335-B2 | Triptolide lignocerate, liposome thereof and preparation method therefor | SHANGHAI WEI ER BIOPHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2026-04-21 | — | — | US | claimed |
| CN-114870026-A | Preparation method of ACE2siRNA medicine for targeting delivery of shRNA by ACE2 | 杭州痴创生物科技有限公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-114832100-A | Preparation method of nCOVsiRNA medicine for delivering shRNA in RBD targeting manner | 杭州痴创生物科技有限公司 | 2022-08-02 | — | — | CN | disclosed |
| CN-114617977-A | ACE2siRNA medicine for targeting delivery of shRNA by ACE2 | 杭州痴创生物科技有限公司 | 2022-06-14 | — | — | CN | disclosed |
| CN-114569712-A | nCOVsiRNA medicine for delivering shRNA in RBD targeting manner | 杭州痴创生物科技有限公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-114569737-A | Screening method of anti-variant strain conserved target nCOVsiRNA delivered by novel vector | 杭州痴创生物科技有限公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-106946975-B | Triptolide derivative and preparation method and preparation thereof | 上海天氏利医药科技有限公司 | 2020-08-14 | — | — | CN | disclosed |
| CN-1744918-A | Polymeric reagents comprising a ketone or a related functional group | NEKTAR THERAPEUTICS AL CORP (US) | 2006-03-08 | — | — | CN | disclosed |
| EP-1352072-A4 | NUCLEIC ACID DELIVERY FORMULATIONS | ZYCOS INC (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20040147466-A1 | Nucleic acid delivery formulations | MGI PHARMA BIOLOGICS, INC. | 2004-07-29 | — | — | US | disclosed |
| EP-1352072-A2 | NUCLEIC ACID DELIVERY FORMULATIONS | Zycos Inc. (US) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002057424-A2 | NUCLEIC ACID DELIVERY FORMULATIONS | ZYCOS INC. (US) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605335-B2 | Triptolide lignocerate, liposome thereof and preparation method therefor | CETP, LYPLA2, LIPA | FAAH 773/4885CES1 79/4885CES2 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.